Safety and high level efficacy of the combination malaria vaccine regimen of RTS,S/AS01B with ChAd-MVA vectored vaccines expressing ME-TRAP

Safety and high level efficacy of the combination malaria vaccine regimen of RTS,S/AS01B with ChAd-MVA vectored vaccines expressing ME-TRAP

Background: The need for a highly efficacious vaccine against Plasmodium falciparum remains pressing. In this controlled human malaria infection (CHMI) study, we assessed the safety, efficacy and immunogenicity of a schedule combining two distinct vaccine types in a staggered immunization regimen: o...

Full description

Bibliographic Details
Main Authors:	Rampling, T, Ewer, K, Bowyer, G, Bliss, C, Edwards, N, Wright, D, Payne, R, Venkatraman, N, Snudden, C, Poulton, I, Roberts, R, Sinden, R, Gerry, S, Lawrie, A, Gilbert, S, Hill, A
Format:	Journal article
Published:	Oxford University Press 2016

Similar Items

Safety and Efficacy of Novel Malaria Vaccine Regimens of RTS,S/AS01B alone, or with Concomitant ChAd63-MVA Vectored Vaccines Expressing ME-TRAP
by: Rampling, T, et al.
Published: (2018)

Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals.
by: Hodgson, S, et al.
Published: (2014)

Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP
by: Rampling, T, et al.
Published: (2016)

Safety and immunogenicity of the heterologous prime-boost ebolavirus vaccine regimen CHAD3-EBO Z and MVA-BN (R) FILO in healthy UK adults
by: Rampling, T, et al.
Published: (2015)

Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African children and infants
by: Bliss, C, et al.
Published: (2016)

Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP
by: Bliss, C, et al.
Published: (2018)

First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children
by: Tiono, AB, et al.
Published: (2018)

Evaluation of the efficacy of chad63-mva vectored vaccines expressing circumsporozoite protein and me-trap against controlled human malaria infection in malaria-naive individuals
by: Hodgson, SH, et al.
Published: (2014)

Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal.
by: Mensah, V, et al.
Published: (2016)

Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.
by: Ogwang, C, et al.
Published: (2013)

A Phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS
by: De Barra, E, et al.
Published: (2014)

Durability of immune responses induced by three leading candidate ebola vaccine regimes; rVSV ZEBOV, ChAd3 EBO Z-MVA BN-Filo and AdHu26.ZEBOV-MVA BN Filo
by: Ewer, K, et al.
Published: (2018)

Phase Ia clinical evaluation of the plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors
by: Sheehy, S, et al.
Published: (2011)

Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors.
by: Sheehy, S, et al.
Published: (2011)

Impact of exposure to malaria and nutritional status on responses to the experimental malaria vaccine ChAd63 MVA ME-TRAP in 5-17 month-old children in Burkina Faso
by: Morter, R, et al.
Published: (2022)

ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans.
by: Sheehy, S, et al.
Published: (2012)

Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors.
by: Sheehy, S, et al.
Published: (2012)

ChAd63-MVA-vectored blood-stage Malaria vaccines targeting MSP1 and AMA1: Assessment of efficacy against mosquito bite challenge in humans
by: Sheehy, S, et al.
Published: (2012)

Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations.
by: Kimani, D, et al.
Published: (2014)

THE RTS,S MALARIA VACCINE What is the efficacy of the RTS,S malaria vaccine?
by: Duncan, C, et al.
Published: (2011)

CXCR3+ T follicular helper cells induced by co-administration of RTS,S/AS01B and viral vectored vaccines are associated with reduced immunogenicity and efficacy against Malaria
by: Ewer (nee Russell), K, et al.
Published: (2018)

A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS.
by: Dunachie, S, et al.
Published: (2006)

Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector.
by: O'Hara, G, et al.
Published: (2012)

Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection.
by: Elias, S, et al.
Published: (2014)

A monovalent chimpanzee adenovirus ebola vaccine boosted with MVA
by: Ewer (nee Russell), K, et al.
Published: (2016)

Safety and immunogenicity of the novel plasmodium falciparum blood-stage vaccine chad63-mva rh5 in a phase ia clinical trial
by: Payne, R, et al.
Published: (2017)

What is the efficacy of the RTS,S malaria vaccine?
by: Duncan, C, et al.
Published: (2011)

What is the efficacy of the RTS,S malaria vaccine?
by: Duncan, C, et al.
Published: (2011)

A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity
by: Rowland, R, et al.
Published: (2012)

Safety and immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I first-in-human trial
by: de Graaf, H, et al.
Published: (2021)

Safety and immunogenicity of a heterologous prime-boost Ebola virus vaccine regimen in healthy adults in the United Kingdom and Senegal
by: Venkatraman, N, et al.
Published: (2018)

Safety and immunogenicity of malaria vectored vaccines given with routine EPI vaccines in Gambian infants and neonates: a randomized controlled trial
by: Mensah, V, et al.
Published: (2017)

Detection of vaccine-induced antibodies to Ebola virus in oral fluid
by: Lambe, T, et al.
Published: (2016)

Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure
by: Biswas, S, et al.
Published: (2014)

RTS,S/AS01 malaria vaccine in African children.
by: Hill, A
Published: (2012)

The future of the RTS,S/AS01 malaria vaccine: an alternative development plan
by: Gosling, R, et al.
Published: (2015)

Rabies vaccine: economical regimens.
by: Warrell, M, et al.
Published: (1993)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.
by: Pathan, A, et al.
Published: (2012)

Comparison of the safety and immunogenicity of a candidate TB vaccine, MVA85A, given by the intramuscular or intradermal route in BCG-vaccinated adults
by: Harris, S, et al.
Published: (2011)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
by: Pathan, A, et al.
Published: (2012)